These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 27012389)

  • 1. Medical Management of Meningiomas: Current Status, Failed Treatments, and Promising Horizons.
    Karsy M; Guan J; Cohen A; Colman H; Jensen RL
    Neurosurg Clin N Am; 2016 Apr; 27(2):249-60. PubMed ID: 27012389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel therapies for meningiomas.
    Wen PY; Drappatz J
    Expert Rev Neurother; 2006 Oct; 6(10):1447-64. PubMed ID: 17078786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea.
    Schrell UM; Rittig MG; Anders M; Koch UH; Marschalek R; Kiesewetter F; Fahlbusch R
    J Neurosurg; 1997 May; 86(5):840-4. PubMed ID: 9126900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in meningioma therapy.
    Norden AD; Drappatz J; Wen PY
    Curr Neurol Neurosci Rep; 2009 May; 9(3):231-40. PubMed ID: 19348712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of chemotherapy and targeted therapy in the treatment of intracranial meningioma.
    Chamberlain MC
    Curr Opin Oncol; 2012 Nov; 24(6):666-71. PubMed ID: 22759739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma.
    Norden AD; Ligon KL; Hammond SN; Muzikansky A; Reardon DA; Kaley TJ; Batchelor TT; Plotkin SR; Raizer JJ; Wong ET; Drappatz J; Lesser GJ; Haidar S; Beroukhim R; Lee EQ; Doherty L; Lafrankie D; Gaffey SC; Gerard M; Smith KH; McCluskey C; Phuphanich S; Wen PY
    Neurology; 2015 Jan; 84(3):280-6. PubMed ID: 25527270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy: What is its role in meningioma?
    Sherman WJ; Raizer JJ
    Expert Rev Neurother; 2012 Oct; 12(10):1189-95; quiz 1196. PubMed ID: 23082735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of unresectable skull base meningiomas with somatostatin analogs.
    Schulz C; Mathieu R; Kunz U; Mauer UM
    Neurosurg Focus; 2011 May; 30(5):E11. PubMed ID: 21529167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma.
    Mason WP; Gentili F; Macdonald DR; Hariharan S; Cruz CR; Abrey LE
    J Neurosurg; 2002 Aug; 97(2):341-6. PubMed ID: 12186462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meningiomas: Overview and New Directions in Therapy.
    Wang N; Osswald M
    Semin Neurol; 2018 Feb; 38(1):112-120. PubMed ID: 29548058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current standing and frontiers of gene therapy for meningiomas.
    De La Garza-Ramos R; Flores-Rodríguez JV; Martínez-Gutiérrez JC; Ruiz-Valls A; Caro-Osorio E
    Neurosurg Focus; 2013 Dec; 35(6):E4. PubMed ID: 24289129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New insights into meningioma: from genetics to trials.
    Vranic A; Peyre M; Kalamarides M
    Curr Opin Oncol; 2012 Nov; 24(6):660-5. PubMed ID: 22820412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical treatment of recurrent meningiomas.
    Chamberlain MC; Barnholtz-Sloan JS
    Expert Rev Neurother; 2011 Oct; 11(10):1425-32. PubMed ID: 21955199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway.
    Schrell UM; Rittig MG; Anders M; Kiesewetter F; Marschalek R; Koch UH; Fahlbusch R
    J Neurosurg; 1997 May; 86(5):845-52. PubMed ID: 9126901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meningioma.
    Fathi AR; Roelcke U
    Curr Neurol Neurosci Rep; 2013 Apr; 13(4):337. PubMed ID: 23463172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted drug therapy for meningiomas.
    Norden AD; Drappatz J; Wen PY
    Neurosurg Focus; 2007; 23(4):E12. PubMed ID: 17961036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An evidence-based treatment algorithm for the management of WHO Grade II and III meningiomas.
    Sun SQ; Hawasli AH; Huang J; Chicoine MR; Kim AH
    Neurosurg Focus; 2015 Mar; 38(3):E3. PubMed ID: 25727225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intracranial meningiomas, the VEGF-A pathway, and peritumoral brain oedema.
    Nassehi D
    Dan Med J; 2013 Apr; 60(4):B4626. PubMed ID: 23651727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
    Mazza E; Brandes A; Zanon S; Eoli M; Lombardi G; Faedi M; Franceschi E; Reni M
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):115-20. PubMed ID: 26659583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic therapy for relapsed/refractory meningioma: Is there potential for antiangiogenic agents?
    Dasanu CA; Samara Y; Codreanu I; Limonadi FM; Hamid O; Alvarez-Argote J
    J Oncol Pharm Pract; 2019 Apr; 25(3):638-647. PubMed ID: 30253729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.